TYK Medicines (HKSE:02410) ROCE %: -73.63% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02410 TYK Medicines Inc HKSE:02410
7 GF Score
Price HK$6.81
! 3 Warning Signs
View Full Analysis

What is TYK Medicines ROCE %?

TYK Medicines HKSE:02410 -4.08% 7 ROCE % is -73.63% as of Dec. 2025. GuruFocus rates HKSE:02410 with a GF Score™ of 7/100. The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. TYK Medicines's annualized ROCE % for the quarter that ended in Dec. 2025 was -73.63%.

TYK Medicines  (HKSE:02410) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

TYK Medicines ROCE % Related Terms

TYK Medicines ROCE % Historical Data

* Premium members only.

The historical data trend for TYK Medicines's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TYK Medicines ROCE % Chart

TYK Medicines Annual Data
Trend Dec22 Dec23 Dec24 Dec25
ROCE %
0.00 0.00 0.00 -54.02

TYK Medicines Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial 0.00 0.00 0.00 -37.21 -73.63
HKSE:02410
7GF Score
TYK Medicines Inc HKSE:02410
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TYK Medicines ROCE % Calculation

TYK Medicines's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-321.537/( ( (977.66 - 308.644) + (861.395 - 340.005) )/ 2 )
=-321.537/( (669.016+521.39)/ 2 )
=-321.537/595.203
=-54.02 %

TYK Medicines's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-407.29/( ( (868.349 - 283.464) + (861.395 - 340.005) )/ 2 )
=-407.29/( ( 584.885 + 521.39 )/ 2 )
=-407.29/553.1375
=-73.63 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -73.63% mean?
TYK Medicines (HKSE:02410) has a ROCE % of -73.63% as of Dec. 2025.
Is TYK Medicines' ROCE % too high?
TYK Medicines' current ROCE % is -73.63%. Overall, TYK Medicines has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does TYK Medicines' ROCE % compare to VRTX and REGN?
TYK Medicines' ROCE % of -73.63% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. TYK Medicines's current ROCE % is -73.63%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TYK Medicines stock overvalued right now?
TYK Medicines (HKSE:02410) has a current ROCE % of -73.63%. The current ROCE % is -73.63%. TYK Medicines' overall GF Score™ is 7/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For TYK Medicines (HKSE:02410), the current ROCE % is -73.63% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TYK Medicines Business Description

Address No.277 Longlan Road, 8th Floor, Building T2, China Eastern Binjiang Center, Xuhui District, Shanghai, CHN
TYK Medicines Inc is a clinical-stage biopharmaceutical company. The company is engaged in drug discovery research and development. The company and its subsidiaries are principally engaged in the research, development, and commercialization of pharmaceutical products. The company has built a pipeline with10 drug candidates, including Core Product TY-9591, five clinical stage products, and four preclinical stage or early clinical development stage.
7GF Score

Get the complete analysis for HKSE:02410

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$6.81
Price